Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Regulatory
59 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Vandetanib | US FDA | Thyroid Gland Medullary Carcinoma | CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. ( 1 ) Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. ( 1 ) | approved | Apr 6, 2011 | openfda |
Data updated 19 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Selpercatinib | 20 | 16 | 4 |
| Vemurafenib | 17 | 14 | 3 |
| Cetuximab | 15 | 8 | 7 |
| Dabrafenib | 11 | 11 | 0 |
| Trametinib | 11 | 11 | 0 |
| Erlotinib | 9 | 6 | 3 |
| Larotrectinib | 5 | 5 | 0 |
| Pralsetinib | 5 | 2 | 3 |
| Afatinib | 4 | 3 | 1 |
| Dactolisib | 4 | 4 | 0 |
| Docetaxel | 4 | 2 | 2 |
| Taselisib | 4 | 3 | 1 |
| Trastuzumab | 4 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 4 |
| 0 |
| Crizotinib | 3 | 3 | 0 |
| Dasatinib | 3 | 3 | 0 |
| Everolimus | 3 | 1 | 1 |
| Fluorouracil | 3 | 3 | 0 |
| Pembrolizumab | 3 | 3 | 0 |
| Perifosine | 3 | 3 | 0 |
| Radiation Therapy | 3 | 2 | 1 |
| RDEA 119 | 3 | 3 | 0 |
| Sorafenib | 3 | 3 | 0 |
| Temsirolimus | 3 | 3 | 0 |
| Alpelisib | 2 | 1 | 1 |
| Aspirin | 2 | 2 | 0 |
| Axitinib | 2 | 0 | 2 |
| Cabozantinib | 2 | 2 | 0 |
| Cisplatin | 2 | 1 | 1 |
| Dabrafenib/Trametinib Regimen | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| Lapatinib | 2 | 2 | 0 |
| MEK Inhibitor CI-1040 | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Panitumumab | 2 | 1 | 1 |
| Pertuzumab | 2 | 2 | 0 |
| Pictilisib | 2 | 2 | 0 |
| PLX4720 | 2 | 2 | 0 |
| Ponatinib | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Tanespimycin | 2 | 2 | 0 |
| Abiraterone Acetate | 1 | 0 | 1 |
| Akt Inhibitor MK2206 | 1 | 1 | 0 |
| Alectinib | 1 | 1 | 0 |
| Alisertib | 1 | 1 | 0 |
| Apitolisib | 1 | 1 | 0 |
| Barasertib | 1 | 1 | 0 |
| Bicalutamide | 1 | 1 | 0 |
| Bimiralisib | 1 | 1 | 0 |
| Capecitabine | 1 | 1 | 0 |
| Celecoxib | 1 | 1 | 0 |
| Copanlisib | 1 | 1 | 0 |
| Durvalumab | 1 | 1 | 0 |
| Entrectinib | 1 | 1 | 0 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 1 | 0 | 1 |
| Erdafitinib | 1 | 1 | 0 |
| Futibatinib | 1 | 1 | 0 |
| Gefitinib | 1 | 1 | 0 |
| GPI-15427 | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| Imatinib Mesylate | 1 | 1 | 0 |
| Infigratinib | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| Leucovorin | 1 | 1 | 0 |
| Leuprolide | 1 | 1 | 0 |
| Linsitinib | 1 | 1 | 0 |
| Nivolumab | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| Paclitaxel | 1 | 1 | 0 |
| Pazopanib | 1 | 1 | 0 |
| PD1 Inhibitor | 1 | 1 | 0 |
| Platinum Compound | 1 | 1 | 0 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Regorafenib | 1 | 1 | 0 |
| Ribociclib | 1 | 1 | 0 |
| Sapanisertib | 1 | 1 | 0 |
| Selumetinib | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Tipifarnib | 1 | 1 | 0 |
| Trastuzumab Emtansine | 1 | 1 | 0 |
| Tretinoin | 1 | 1 | 0 |
| Zoledronic Acid | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.